- Avicanna’s (AVCN) subsidiary Santa Marta Golden Hemp, has completed its first commercial export of feminized cannabis seeds to Lesotho
- These seeds were all developed, standardized and produced through Avicanna’s vertical integration at SMGH located in Santa Marta, Colombia
- The standardized and feminized seeds are a part of the Aureus product portfolio
- Avicanna is an innovative, commercial-stage international biopharmaceutical company
- Avicanna Inc. (AVCN) was down 12.73 per cent, trading at C$0.24 per share at 11:35 am ET
Avicanna’s (AVCN) subsidiary Santa Marta Golden Hemp has completed its first commercial export of feminized cannabis seeds to Lesotho.
These seeds were all developed, standardized and produced through Avicanna’s vertical integration at SMGH in Santa Marta, Colombia.
The standardized and feminized seeds are a part of the Aureus product portfolio. The portfolio includes CBD, CBG and THC seeds, resins or whole plant crude oils, cannabinoid distillates, and isolated cannabinoids.
Lucas Nosiglia, President of Avicanna LATAM, commented on the news.
“We are happy to see the demand for our proprietary genetics grow internationally. The culmination of our seed development and standardization efforts provides our international partners with the opportunity to cultivate federally registered, reliable and consistent cultivars across various environments and landscapes.”
Avicanna’s supply chain business unit provides a consistent source of cannabinoid raw materials for the global marketplace. These include active pharmaceutical ingredients and feminized seeds for Avicanna’s cosmetic, medical, and pharmaceutical products. It also supplies to the company’s partners around the world.
Aureus-branded products are cultivated, extracted, and manufactured by Avicanna’s subsidiaries in Colombia. It leverages optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically and sustainably with USDA organic and GACP certifications.
Avicanna is an innovative, commercial-stage international biopharmaceutical company. It focuses on advancing and commercializing evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform, including R&D and clinical development. It has led to the commercialization of more than thirty products across various market segments.
Avicanna Inc. (AVCN) was down 12.73 per cent, trading at C$0.24 per share at 11:35 am ET.
